Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Nuvalent News

Aktie
WKN:  A3CWDU ISIN:  US6707031075 US-Symbol:  NUVL Branche:  Biotechnologie Land:  USA
107,66 $
+3,82 $
+3,68%
91,517 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
5,06 Mrd. €
Streubesitz
-
KGV
-18,06
Index-Zuordnung
-

Nuvalent News

07.09.25 - PR Newswire
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 PR Newswire
28.08.25 - PR Newswire
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025 PR Newswire
13.08.25 - PR Newswire
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential ...
07.08.25 - PR Newswire
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results PR Newswire
21.07.25 - PR Newswire
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-​positive NSCLC PR Newswire
24.06.25 - PR Newswire
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC PR Newswire
23.06.25 - PR Newswire
Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
Nuvalent Announces Timing of Pivotal Data for TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib PR Newswire
18.06.25 - PR Newswire
Nuvalent Appoints Christy Oliger to Board of Directors
Nuvalent Appoints Christy Oliger to Board of Directors PR Newswire
08.05.25 - PR Newswire
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results PR Newswire
29.04.25 - PR Newswire
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor PR Newswire
23.04.25 - PR Newswire
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting ...

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »